3 Houston innovators to know this week

who's who

This week's roundup of Houston innovators includes Sarah Groen of Bell & Bly Travel, Alex Reed of Fluence Analytics, and Bettina Beech of UH. Courtesy photos

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from travel to analytics— recently making headlines in Houston innovation.

Sarah Groen, founder of Bell and Bly Travel

Sarah Groen, travel entrepreneur and longtime Houston tech ecosystem member, joins the Houston Innovators Podcast. Photo courtesy of Bell and Bly Travel

It's been a scary time for travel-related businesses, and Sarah Groen has had to get innovative to maintain her business as a travel adviser. Lucky for Groen, who has a long career in tech and innovation, she had all the right pivots, including offering digital travel packages, launching a new podcast, and more.

"During COVID, a lot of businesses either shutdown or took a pause, but we accelerated," Groen says.

Groen her career on the Houston Innovators Podcast. She also gives some strategic advice for founders — like trusting your gut and reading the signs when it comes to product-market fit — on the podcast. Click here to read more and stream the episode.

Alex Reed, co-founder and CEO of Fluence Analytics

Alex Reed joined InnovationMap for a Q&A on the company's move to Houston and its growth plans. Photo courtesy of Fluence Analytics

Alex Reed watched his father work in the labs on his research as he grew up, but he realized his future wasn't in the lab. Instead, he launched a career in taking that research and turning it into a company.

Founded in 2012 in New Orleans, Fluence Analytics has entered its next phase of growth by moving its headquarters to Houston following a $7.5 million venture capital raise.

We're working with the Houston of today, but also the Houston of tomorrow," Reed tells InnovationMap in a Q&A. Click here to read more.

Bettina Beech, chief population health officer at the University of Houston

Bettina Beech is a newly named AIM-AHEAD coordinating center team member. Photo via UH.edu

The University of Houston has joined in on a national initiative to increase the diversity of artificial intelligence researchers, according to a news release from the school. Unfortunately, AI — designed by humans — mimics human decision making through its choice of algorithms. This means that the same biases humans deal with have made it into the AI decision making too. These gaps can lead to continued disparities and inequities for underrepresented communities especially in regards to health care, job hiring, and more.

"Beyond health care, AI has been used in areas from facial recognition to self-driving cars and beyond, but there is an extreme lack of diversity among the developers of AI/ML tools. Many studies have shown that flawed AI systems and algorithms perpetuate gender and racial biases and have resulted in untoward outcomes," says Bettina Beech, chief population health officer at the University of Houston and newly named AIM-AHEAD coordinating center team member.

The initiative will bring together collaborators and experts across AI and machine learning, health equity research, data science training, data infrastructure and more. The other universities involved include: University of Colorado-Anschutz Medical Center in Aurora; University of California, Los Angeles; Meharry Medical College in Nashville; Morehouse School of Medicine in Atlanta; Johns Hopkins University, and Vanderbilt University Medical Center. Click here to read more.

Sarah Groen, travel entrepreneur and longtime Houston tech ecosystem member, joins the Houston Innovators Podcast. Photo courtesy of Bell and Bly Travel

Innovative travel adviser talks Houston tech and advice for female founders

houston innovators podcast episode 104

When the pandemic hit, it's safe to say that everyone in the travel industry panicked. Sarah Groen, who founded her company Bell and Bly Travel in 2017, caters her expertise to planning luxury travel experiences, and she didn't want her clients to forget about her expertise as the uncertainty of the pandemic continued. So, she got creative.

"Every single client who had a trip canceled, we sent them a digital package to help them feel like they were traveling," Groen says on this week's episode of the Houston Innovators Podcast. For example, if a client's trip to Italy canceled, Groen and her staff provided links to recipes of Italian dishes, virtual museum tours, and more.

"We didn't make money on that," Groen says. "We spent money to be able to have the bandwidth to be able to do that for our clients."

It's during this time thar Groen also launched her podcast, Luxury Travel Insider, where she gathers experts to discuss destinations.

It's these innovative endeavors that put Groen and Bell and Bly Travel on the map for Virtuoso's award — which Groen describes as the Oscars of the travel industry. She took home the title of "most innovative travel advisor" at the 2021 awards.

"During COVID, a lot of businesses either shutdown or took a pause, but we accelerated," Groen says.

The award is incredibly special to Groen she says especially to her background in tech. A native Houstonian, Groen went to the West Coast for her education. Despite loving her hometown, she says she returned kicking and screaming because she wanted to do something entrepreneurial, and Houston didn't yet have much to speak of in terms of a startup ecosystem.

So, like any good entrepreneur who sees a need in the market, she did it herself and co-founded Surge, an energy-focused accelerator. But it was a struggle to get momentum.

"But at that time, we couldn't even get the mayor to pay attention to us. We had people applying to our program and moving their companies from other cities and countries in some cases," Groen says. "But I think Surge starting was a big turning point."

Surge — which was co-founded by Kirk Coburn, who now is the investment director for Shell Ventures — officially shut down in 2016.

But things have changed within the Houston innovation ecosystem, and Groen discusses the transformation as she's observed it on the show. She also gives some strategic advice for founders — like trusting your gut and reading the signs when it comes to product-market fit — on the podcast. Listen to the full interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.


Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

How Houston's innovation sector fared in 2025 Texas legislative session

That's a Wrap

The Greater Houston Partnership is touting a number of victories during the recently concluded Texas legislative session that will or could benefit the Houston area. They range from billions of dollars for dementia research to millions of dollars for energy projects.

“These wins were only possible through deep collaboration, among our coalition partners, elected officials, business and community leaders, and the engaged members of the Partnership,” according to a partnership blog post. “Together, we’ve demonstrated how a united voice for Houston helps drive results that benefit all Texans.”

In terms of business innovation, legislators carved out $715 million for nuclear, semiconductor, and other economic development projects, and a potential $1 billion pool of tax incentives through 2029 to support research-and-development projects. The partnership said these investments “position Houston and Texas for long-term growth.”

Dementia institute

One of the biggest legislative wins cited by the Greater Houston Partnership was passage of legislation sponsored by Sen. Joan Huffman, a Houston Republican, to provide $3 billion in funding over 10 years for the Dementia Prevention and Research Institute of Texas. Voters will be asked in November to vote on a ballot initiative that would set aside $3 billion for the new institute.

The dementia institute would be structured much like the Cancer Prevention and Research Institute of Texas (CPRIT), a state agency that provides funding for cancer research in the Lone Star State. Since its founding in 2008, CPRIT has awarded nearly $3.9 billion in research grants.

“By establishing the Dementia Prevention and Research Institute of Texas, we are positioning our state to lead the charge against one of the most devastating health challenges of our time,” Huffman said. “With $3 billion in funding over the next decade, we will drive critical research, develop new strategies for prevention and treatment, and support our healthcare community. Now, it’s up to voters to ensure this initiative moves forward.”

More than 500,000 Texans suffer from some form of dementia, including Alzheimer’s disease, according to Lt. Gov. Dan Patrick.

“With a steadfast commitment, Texas has the potential to become a world leader in combating [dementia] through the search for effective treatments and, ultimately, a cure,” Patrick said.

Funding for education

In the K-12 sector, lawmakers earmarked an extra $195 million for Houston ISD, $126.7 million for Cypress-Fairbanks ISD, $103.1 million for Katy ISD, $80.6 million for Fort Bend ISD, and $61 million for Aldine ISD, the partnership said.

In higher education, legislators allocated:

     
  • $1.17 billion for the University of Houston College of Medicine, University of Texas Health Science Center at Houston, UT MD Anderson Cancer Center, and Baylor College of Medicine
  • $922 million for the University of Houston System
  • $167 million for Texas Southern University
  • $10 million for the Center for Biotechnology at San Jacinto College.

Infrastructure

In the infrastructure arena, state lawmakers:

     
  • Approved $265 million for Houston-area water and flood mitigation projects, including $100 million for the Lynchburg Pump Station
  • Created the Lake Houston Dredging and Maintenance District
  • Established a fund for the Gulf Coast Protection District to supply $550 million for projects to make the coastline and ship channel more resilient

"Nuclear power renaissance"

House Bill 14 (HB 14) aims to lead a “nuclear power renaissance in the United States,” according to Texas Gov. Greg Abbott’s office. HB 14 establishes the Texas Advanced Nuclear Energy Office, and allocates $350 million for nuclear development and deployment. Two nuclear power plants currently operate in Texas, generating 10 percent of the energy that feeds the Electric Reliability Council Texas (ERCOT) power grid.

“This initiative will also strengthen Texas’ nuclear manufacturing capacity, rebuild a domestic fuel cycle supply chain, and train the future nuclear workforce,” Abbott said in a news release earlier this year.

One of the beneficiaries of Texas’ nuclear push could be Washington, D.C.-based Last Energy, which plans to build 30 micro-nuclear reactors near Abilene to serve power-gobbling data centers across the state. Houston-based Pelican Energy Partners also might be able to take advantage of the legislation after raising a $450 million fund to invest in companies that supply nuclear energy services and equipment.

Reed Clay, president of the Texas Nuclear Alliance, called this legislation “the most important nuclear development program of any state.”

“It is a giant leap forward for Texas and the United States, whose nuclear program was all but dead for decades,” said Clay. “With the passage of HB 14 and associated legislation, Texas is now positioned to lead a nuclear renaissance that is rightly seen as imperative for the energy security and national security of the United States.”

---

A version of this article first appeared on EnergyCapitalHTX.com.

View All Listings